C-lock-GGFG-Dxd

C-lock-GGFG-Dxd Catalog number: BADC-01419

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

C-lock-GGFG-Dxd is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs).

Category
ADCs Cytotoxin with Linkers
Product Name
C-lock-GGFG-Dxd
Catalog Number
BADC-01419
Molecular Formula
C53H51Br2FN10O11
Molecular Weight
1182.86
C-lock-GGFG-Dxd

Ordering Information

Catalog Number Size Price Quantity
BADC-01419 -- $-- Inquiry
Description
C-lock-GGFG-Dxd is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs).
IUPAC Name
N-((S)-10-benzyl-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadecan-16-yl)-2,3-bis(bromomethyl)quinoxaline-6-carboxamide
InChI
InChI=1S/C53H51Br2FN10O11/c1-3-53(75)32-15-41-48-30(22-66(41)51(73)31(32)23-77-52(53)74)47-35(12-10-29-26(2)33(56)16-37(65-48)46(29)47)63-45(70)24-76-25-60-43(68)20-59-50(72)38(13-27-7-5-4-6-8-27)64-44(69)21-57-42(67)19-58-49(71)28-9-11-34-36(14-28)62-40(18-55)39(17-54)61-34/h4-9,11,14-16,35,38,75H,3,10,12-13,17-25H2,1-2H3,(H,57,67)(H,58,71)(H,59,72)(H,60,68)(H,63,70)(H,64,69)/t35-,38-,53-/m0/s1
InChIKey
QKALRJDZWWGYSQ-XLOSCTDISA-N

C-lock-GGFG-Dxd, a cutting-edge drug conjugate in the oncology domain, is tailored to deliver cytotoxic agents to cancer cells with exceptional precision. Here are four key applications of C-lock-GGFG-Dxd:

Targeted Cancer Therapy: Engineered with precision, C-lock-GGFG-Dxd homes in on specific cancer cell receptors, ensuring the exact delivery of the cytotoxic drug Dxd to the tumor site. This targeted strategy minimizes harm to healthy tissues and diminishes side effects compared to conventional chemotherapy. By coupling Dxd with an antibody or a similar targeting moiety, C-lock-GGFG-Dxd achieves heightened effectiveness in annihilating tumors.

Multidrug Resistance Management: Confronting multidrug resistance (MDR) in cancer treatment, C-lock-GGFG-Dxd circumvents the usual drug efflux mechanisms employed by resistant cancer cells. The deployment of a specialized linker (GGFG) guarantees the stable transportation of Dxd specifically to the tumor, bolstering its therapeutic impact even in resistant cancer phenotypes.

Combination Therapy: Integrating seamlessly into combination therapy protocols with other anticancer agents, C-lock-GGFG-Dxd synergizes with additional drugs or treatment methodologies like radiation therapy, amplifying the overall treatment efficacy. By combining C-lock-GGFG-Dxd with other therapeutic modalities, a more comprehensive eradication of tumor cells can be achieved, ultimately enhancing patient outcomes.

Clinical Research and Development: In the realm of clinical research, C-lock-GGFG-Dxd plays a pivotal role in shaping the future of antibody-drug conjugates (ADCs). Researchers leverage its potential to investigate pharmacokinetics, biodistribution, and therapeutic indices, aiming to refine ADC configurations. This research endeavor lays the foundation for the creation of superior targeted oncological interventions with enhanced safety profiles and boosted efficacy.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Historical Records: C-lock-GGFG-Dxd
Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Resources & Supports
Inquiry Basket